Dopamine agonists

Area of Science:

• Neurology
• Pharmacology

Background:

• Parkinson's disease (PD) is a progressive neurodegenerative disorder.
• Dopamine deficiency is a key pathological feature of PD.
• Current treatments aim to restore dopaminergic neurotransmission.

Purpose of the Study:

• To compare dopamine agonists with levodopa therapy for Parkinson's disease.
• To review the features and costs of available dopamine agonists.
• To discuss the role of dopamine agonists in early, middle, and late-stage PD.

Main Methods:

• Comparative review of therapeutic options.
• Analysis of pharmacological properties.
• Discussion of clinical trial data and cost-effectiveness.

Main Results:

• Dopamine agonists offer an alternative to levodopa for PD management.
• Specific agonists (bromocriptine, pergolide, pramipexole, ropinirole) and apomorphine are evaluated.
• Advantages and disadvantages relative to levodopa are presented.

Conclusions:

• Dopamine agonists are valuable in all stages of Parkinson's disease.
• Therapeutic choice depends on individual patient factors and drug characteristics.
• Further investigation of agents like apomorphine is ongoing.